Exercise and apulian hypocaloric diet affect adipokine changes and gastric banding-induced weight loss: A prospective study on severe obese subjects.
Apulian diet
Bariatric surgery
Lifestyle
Obesity
Physical activity
Resistin
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
01
08
2019
revised:
18
02
2020
accepted:
19
02
2020
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
11
3
2020
Statut:
epublish
Résumé
Adiponectin and Resistin correlate with insulin sensitivity and cardiovascular risk, respectively. This study aimed to identify lifestyle factors that modulate changes in Adiponectin and Resistin levels after gastric banding positioning (LapGB). Before (T0), 3 months (T3), 6 months (T6), and 12 months (T12) after LapGB, serum Adiponectin and Resistin levels were evaluated in a single-centre prospective study including a cohort of 27 non-diabetic obese subjects (S-Ob, BMI ≥35 kg/m At baseline, Resistin levels were significantly higher and Adiponectin levels significantly lower in S-Ob than in controls. After surgery, group 1 showed a 50.2% excess weight loss (%EWL), significantly decreased Resistin levels at T12 and increased Adiponectin levels at both T6 and T12 as compared with baseline. Group 2 showed 24.6 %EWL at T12, decreased Adiponectin levels at T6 and T12 as compared with baseline, but unaltered Resistin levels. After surgery, group 1 followed aphypoD/phA, while group 2 did not. LapGB fails to improve cardiovascular risk markers (Resistin) in S-Ob not improving lifestyle. Future studies might investigate these findings in a larger cohort and display whether aphypoD is more effective than other dietary intervention on cardiovascular risk in subjects undergoing LapGB or other Bariatric procedures.
Sections du résumé
BACKGROUND
BACKGROUND
Adiponectin and Resistin correlate with insulin sensitivity and cardiovascular risk, respectively. This study aimed to identify lifestyle factors that modulate changes in Adiponectin and Resistin levels after gastric banding positioning (LapGB).
MATERIALS AND METHODS
METHODS
Before (T0), 3 months (T3), 6 months (T6), and 12 months (T12) after LapGB, serum Adiponectin and Resistin levels were evaluated in a single-centre prospective study including a cohort of 27 non-diabetic obese subjects (S-Ob, BMI ≥35 kg/m
RESULTS
RESULTS
At baseline, Resistin levels were significantly higher and Adiponectin levels significantly lower in S-Ob than in controls. After surgery, group 1 showed a 50.2% excess weight loss (%EWL), significantly decreased Resistin levels at T12 and increased Adiponectin levels at both T6 and T12 as compared with baseline. Group 2 showed 24.6 %EWL at T12, decreased Adiponectin levels at T6 and T12 as compared with baseline, but unaltered Resistin levels. After surgery, group 1 followed aphypoD/phA, while group 2 did not.
CONCLUSIONS
CONCLUSIONS
LapGB fails to improve cardiovascular risk markers (Resistin) in S-Ob not improving lifestyle. Future studies might investigate these findings in a larger cohort and display whether aphypoD is more effective than other dietary intervention on cardiovascular risk in subjects undergoing LapGB or other Bariatric procedures.
Identifiants
pubmed: 32153773
doi: 10.1016/j.amsu.2020.02.005
pii: S2049-0801(20)30018-2
pmc: PMC7052402
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10-15Informations de copyright
© 2020 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
Déclaration de conflit d'intérêts
Authors declare that they have no competing financial interests in relation to the work described.
Références
Nutr Hosp. 2017 Sep 14;34(5):1333-1337
pubmed: 29280648
Surg Endosc. 2011 Jun;25(6):1962-8
pubmed: 21181202
Am J Clin Nutr. 2010 Nov;92(5):1189-96
pubmed: 20810976
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
JAMA. 2013 Dec 11;310(22):2416-25
pubmed: 24189773
Lancet. 2015 Sep 5;386(9997):964-73
pubmed: 26369473
N Engl J Med. 2004 Dec 23;351(26):2683-93
pubmed: 15616203
Horm Metab Res. 2015 Jan;47(1):84-7
pubmed: 25388925
Circulation. 2003 Aug 12;108(6):736-40
pubmed: 12874180
Atherosclerosis. 2005 Oct;182(2):241-8
pubmed: 16159596
JAMA. 2014 Jun 11;311(22):2297-304
pubmed: 24915261
JAMA. 2018 Jan 16;319(3):255-265
pubmed: 29340679
Circ J. 2017 Sep 25;81(10):1528-1536
pubmed: 28883215
Sports Med. 2010 Jul 1;40(7):565-600
pubmed: 20545381
J Clin Endocrinol Metab. 2007 Sep;92(9):3719-27
pubmed: 17595250
Nat Rev Endocrinol. 2015 Aug;11(8):465-77
pubmed: 26055046
Surg Obes Relat Dis. 2007 Sep-Oct;3(5):496-502; discussion 502
pubmed: 17903768
J Clin Endocrinol Metab. 2010 Aug;95(8):3701-10
pubmed: 20484490
Int J Obes (Lond). 2012 Mar;36(3):342-7
pubmed: 21610696
Diabetes Metab. 2019 Sep;45(4):356-362
pubmed: 30268840
Ann Hepatol. 2017 Oct 28;16(Suppl. 1: s3-105.):s68-s82
pubmed: 29080342
Int J Epidemiol. 1997;26 Suppl 1:S152-60
pubmed: 9126543
Atherosclerosis. 2007 Jul;193(1):121-8
pubmed: 16814296
Diabetologia. 2008 Jan;51(1):155-64
pubmed: 17960360
Diabetes Care. 2007 Mar;30(3):719-21
pubmed: 17327348
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Nutr Metab (Lond). 2015 Dec 30;12:63
pubmed: 26719755
Obes Surg. 1997 Jun;7(3):189-97
pubmed: 9730547
Kardiol Pol. 2014;72(2):181-6
pubmed: 23633273
J Atheroscler Thromb. 2011;18(2):108-14
pubmed: 21071880
Diabetes Care. 2016 Nov;39(11):1925-1931
pubmed: 27573937
Int J Surg. 2017 Oct;46:198-202
pubmed: 28890409
Obes Facts. 2014;7(5):322-8
pubmed: 25485991
J Sci Med Sport. 2007 Feb;10(1):45-51
pubmed: 16807105
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Eur J Clin Invest. 2018 Sep;48(9):e12997
pubmed: 29995306
J Clin Endocrinol Metab. 2003 Nov;88(11):5452-5
pubmed: 14602788
Coron Artery Dis. 2009 Jan;20(1):33-9
pubmed: 18997620
Obes Surg. 1996 Jun;6(3):206-213
pubmed: 10729861
Circulation. 2013 Jan 22;127(3):340-8
pubmed: 23258601
PLoS One. 2015 Feb 13;10(2):e0118071
pubmed: 25679378
Nature. 2001 Jan 18;409(6818):307-12
pubmed: 11201732